menu
    • menu
    [{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Collaboration","leadProduct":"177-Lu PNT2002","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":2.1200000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.1200000000000001,"dosageForm":"Infusion","sponsorNew":"Lantheus Holding \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus Holding \/ Lantheus Holding"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Point Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"177-Lu PNT2002","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantheus Holding \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus Holding \/ Lantheus Holding"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Point Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"177-Lu PNT2002","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantheus Holding \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus Holding \/ Point Biopharma"},{"orgOrder":0,"company":"Lantheus Medical Imaging","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"177-Lu PNT2002","moa":"Beta-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lantheus Medical Imaging","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantheus Medical Imaging \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Lantheus Medical Imaging \/ Eli Lilly"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":2.1200000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.1200000000000001,"dosageForm":"Infusion","sponsorNew":"Lantheus Holding \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus Holding \/ Lantheus Holding"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Collaboration","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lantheus Holding \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Lantheus Holding \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Lantheus Medical Imaging","sponsor":"Lantheus Medical Imaging","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F DCFPyL","moa":"PSMA","graph1":"Oncology","graph2":"Phase II","graph3":"Lantheus Medical Imaging","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lantheus Medical Imaging \/ Lantheus Medical Imaging","highestDevelopmentStatusID":"8","companyTruncated":"Lantheus Medical Imaging \/ Lantheus Medical Imaging"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Lantheus Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F DCFPyL","moa":"PSMA","graph1":"Oncology","graph2":"Phase IV","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantheus Holding \/ Lantheus Holding","highestDevelopmentStatusID":"11","companyTruncated":"Lantheus Holding \/ Lantheus Holding"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Lantheus Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F DCFPyL","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantheus Holding \/ Lantheus Holding","highestDevelopmentStatusID":"6","companyTruncated":"Lantheus Holding \/ Lantheus Holding"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Lantheus Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"18-F DCFPyL","moa":"PSMA","graph1":"Oncology","graph2":"Phase II","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lantheus Holding \/ Lantheus Holding","highestDevelopmentStatusID":"8","companyTruncated":"Lantheus Holding \/ Lantheus Holding"},{"orgOrder":0,"company":"Lantheus Medical Imaging","sponsor":"Lantheus Medical Imaging","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F Piflufolastat","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Lantheus Medical Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantheus Medical Imaging \/ Lantheus Medical Imaging","highestDevelopmentStatusID":"6","companyTruncated":"Lantheus Medical Imaging \/ Lantheus Medical Imaging"},{"orgOrder":0,"company":"Lantheus Medical Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F Piflufolastat","moa":"PSMA","graph1":"Oncology","graph2":"Phase IV","graph3":"Lantheus Medical Imaging","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lantheus Medical Imaging \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lantheus Medical Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Lantheus Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F PSMA","moa":"PSMA","graph1":"Oncology","graph2":"Phase II","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lantheus Holding \/ Lantheus Holding","highestDevelopmentStatusID":"8","companyTruncated":"Lantheus Holding \/ Lantheus Holding"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Perspective Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"212-Pb VMT-alpha-NET","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lantheus Holding","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Lantheus Holding \/ Perspective Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Lantheus Holding \/ Perspective Therapeutics"},{"orgOrder":0,"company":"Lantheus Medical Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"64-Cu LNTH-1363S","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lantheus Medical Imaging","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantheus Medical Imaging \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lantheus Medical Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Lantheus Medical Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"Piflufolastat","moa":"PSMA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Lantheus Medical Imaging","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantheus Medical Imaging \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lantheus Medical Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantheus Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus Holding \/ Undisclosed"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Evergreen Theragnostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Acquisition","leadProduct":"177-Lu EVG-321","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantheus Holding","amount2":1,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Lantheus Holding \/ Lantheus Holding","highestDevelopmentStatusID":"4","companyTruncated":"Lantheus Holding \/ Lantheus Holding"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2024","type":"Private Placement","leadProduct":"68-Ga Trivehexin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lantheus Holding","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Lantheus Holding \/ Lantheus Holding","highestDevelopmentStatusID":"6","companyTruncated":"Lantheus Holding \/ Lantheus Holding"}]

    Find Clinical Drug Pipeline Developments & Deals by Lantheus Holding

    Menu

    Lantheus Holding

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lantheus Medical Imaging

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Lantheus Medical Imaging

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piflufolastat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Piflufolastat F 18 PET/CT in Patients with Suspected, or at High Risk for Metastatic ccRCC

                            Details : Piflufolastat is a Radiolabelled Compounds drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Carcinoma, Renal Cell.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            July 25, 2025

                            Lead Product(s) : Piflufolastat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lantheus Holding

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu EVG-321

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Evergreen Theragnostics

                            Deal Size : $1,002.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lantheus to Acquire Evergreen Theragnostics

                            Details : Through the acquisition, Lantheus will leverage Evergreen radiolabelled product pipeline, which includes EVG-321 (177Lu-EVG-321), is being evaluated for small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : $250.0 million

                            January 28, 2025

                            Lead Product(s) : 177-Lu EVG-321

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Evergreen Theragnostics

                            Deal Size : $1,002.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lantheus Holding

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga Trivehexin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Radiopharm Theranostics

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Radiopharm Receives Strategic Investment for up to A$18 million

                            Details : The company will use the net proceeds of Lantheus’ investment for drug advancement RAD301 ([68Ga]-Trivehexin), which is being evaluated for treating pancreatic neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            June 19, 2024

                            Lead Product(s) : 68-Ga Trivehexin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Radiopharm Theranostics

                            Deal Size : $18.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lantheus Medical Imaging

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Lantheus Medical Imaging

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 64-Cu LNTH-1363S

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

                            Details : 64-Cu LNTH-1363S is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Sarcoma.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            March 07, 2024

                            Lead Product(s) : 64-Cu LNTH-1363S

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lantheus Holding

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Dotatate Lutenium

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lantheus Announces Acceptance of ANDA for Generic LUTATHERA®

                            Details : Lutathera-Generic (Lutetium Lu 177 Dotatate) is a radiolabeled somatostatin analog for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

                            Product Name : Lutathera-Generic

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 11, 2024

                            Lead Product(s) : 177-Lu Dotatate Lutenium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lantheus Holding

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212-Pb VMT-alpha-NET

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Perspective Therapeutics

                            Deal Size : $61.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lantheus Expands Radiopharmaceutical Oncology Pipeline through Strategic Agreements

                            Details : Under the agreement, Lantheus obtains an exclusive license for Perspective’s Pb212-VMT-⍺-NET, a clinical-stage alpha therapy developed for the treatment of neuroendocrine tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $28.0 million

                            January 09, 2024

                            Lead Product(s) : 212-Pb VMT-alpha-NET

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Perspective Therapeutics

                            Deal Size : $61.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lantheus Holding

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu PNT2002

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Point Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castrat...

                            Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy under phase 3 clinical development for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            December 18, 2023

                            Lead Product(s) : 177-Lu PNT2002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Point Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lantheus Holding

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F DCFPyL

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Recipient : Brigham and Women's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

                            Details : 18-F DCFPyL is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            October 25, 2023

                            Lead Product(s) : 18-F DCFPyL

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Recipient : Brigham and Women's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lantheus Medical Imaging

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Lantheus Medical Imaging

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F Piflufolastat

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

                            Details : 18-F Piflufolastat is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            October 10, 2023

                            Lead Product(s) : 18-F Piflufolastat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lantheus Medical Imaging

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Lantheus Medical Imaging

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu PNT2002

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PS...

                            Details : 177-Lu PNT2002 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            September 13, 2023

                            Lead Product(s) : 177-Lu PNT2002

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth